Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
grade F 29.67 3.67% 1.05
MYGN closed up 3.67 percent on Friday, January 18, 2019, on 45 percent of normal volume.

Earnings due: Feb 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical MYGN trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Crossed Above 20 DMA Bullish 0.00%
Jan 17 Inside Day Range Contraction 3.67%
Jan 16 Fell Below 20 DMA Bearish 5.14%
Jan 16 180 Bearish Setup Bearish Swing Setup 5.14%
Jan 16 Outside Day Range Expansion 5.14%
Jan 15 Crossed Above 20 DMA Bullish 1.12%
Jan 15 Calm After Storm Range Contraction 1.12%
Jan 15 Narrow Range Bar Range Contraction 1.12%
Jan 14 Fell Below 20 DMA Bearish 2.59%

Older signals for MYGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Is MYGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 50.44
52 Week Low 26.8
Average Volume 1,037,141
200-Day Moving Average 37.618
50-Day Moving Average 30.403
20-Day Moving Average 29.0385
10-Day Moving Average 29.312
Average True Range 1.4016
ADX 17.87
+DI 24.1839
-DI 25.1905
Chandelier Exit (Long, 3 ATRs ) 28.2052
Chandelier Exit (Short, 3 ATRs ) 31.0048
Upper Bollinger Band 31.077
Lower Bollinger Band 27.0
Percent B (%b) 0.65
BandWidth 14.039981
MACD Line -0.5458
MACD Signal Line -0.7068
MACD Histogram 0.161
Fundamentals Value
Market Cap 2.03 Billion
Num Shares 68.6 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 92.72
Price-to-Sales 3.01
Price-to-Book 2.98
PEG Ratio 3.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.16
Resistance 3 (R3) 31.00 30.36 30.91
Resistance 2 (R2) 30.36 29.98 30.43 30.82
Resistance 1 (R1) 30.01 29.74 30.19 30.17 30.74
Pivot Point 29.37 29.37 29.45 29.44 29.37
Support 1 (S1) 29.02 28.99 29.20 29.18 28.60
Support 2 (S2) 28.38 28.75 28.45 28.52
Support 3 (S3) 28.03 28.38 28.43
Support 4 (S4) 28.19